STAA
Price
$20.83
Change
-$0.99 (-4.54%)
Updated
Jan 15, 12:11 PM (EDT)
Capitalization
1.08B
41 days until earnings call
Intraday BUY SELL Signals
XRAY
Price
$12.44
Change
+$0.09 (+0.73%)
Updated
Jan 15, 12:25 PM (EDT)
Capitalization
2.47B
42 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

STAA vs XRAY

Header iconSTAA vs XRAY Comparison
Open Charts STAA vs XRAYBanner chart's image
STAAR Surgical
Price$20.83
Change-$0.99 (-4.54%)
Volume$3.93K
Capitalization1.08B
DENTSPLY SIRONA
Price$12.44
Change+$0.09 (+0.73%)
Volume$4.01K
Capitalization2.47B
STAA vs XRAY Comparison Chart in %
STAA
Daily Signal:
Gain/Loss:
XRAY
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
STAA vs. XRAY commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is STAA is a Hold and XRAY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (STAA: $21.82 vs. XRAY: $12.35)
Brand notoriety: STAA and XRAY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: STAA: 84% vs. XRAY: 91%
Market capitalization -- STAA: $1.08B vs. XRAY: $2.47B
STAA [@Pharmaceuticals: Other] is valued at $1.08B. XRAY’s [@Pharmaceuticals: Other] market capitalization is $2.47B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $193.82B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $12.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

STAA’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).

  • STAA’s FA Score: 0 green, 5 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, XRAY is a better buy in the long-term than STAA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

STAA’s TA Score shows that 4 TA indicator(s) are bullish while XRAY’s TA Score has 5 bullish TA indicator(s).

  • STAA’s TA Score: 4 bullish, 3 bearish.
  • XRAY’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, STAA is a better buy in the short-term than XRAY.

Price Growth

STAA (@Pharmaceuticals: Other) experienced а -1.67% price change this week, while XRAY (@Pharmaceuticals: Other) price change was -0.16% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.83%. For the same industry, the average monthly price growth was +0.69%, and the average quarterly price growth was -0.06%.

Reported Earning Dates

STAA is expected to report earnings on Feb 25, 2026.

XRAY is expected to report earnings on Feb 26, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-0.83% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XRAY($2.47B) has a higher market cap than STAA($1.08B). XRAY YTD gains are higher at: 8.049 vs. STAA (-5.500). STAA has higher annual earnings (EBITDA): -54.23M vs. XRAY (-433M). XRAY has more cash in the bank: 1.27B vs. STAA (193M). STAA has less debt than XRAY: STAA (39.1M) vs XRAY (2.48B). XRAY has higher revenues than STAA: XRAY (3.62B) vs STAA (231M).
STAAXRAYSTAA / XRAY
Capitalization1.08B2.47B44%
EBITDA-54.23M-433M13%
Gain YTD-5.5008.049-68%
P/E Ratio49.73N/A-
Revenue231M3.62B6%
Total Cash193M1.27B15%
Total Debt39.1M2.48B2%
FUNDAMENTALS RATINGS
STAA vs XRAY: Fundamental Ratings
STAA
XRAY
OUTLOOK RATING
1..100
588
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
6262
P/E GROWTH RATING
1..100
8987
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for STAA (86). This means that XRAY’s stock grew significantly faster than STAA’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as STAA (100). This means that XRAY’s stock grew similarly to STAA’s over the last 12 months.

STAA's SMR Rating (96) in the Medical Specialties industry is in the same range as XRAY (97). This means that STAA’s stock grew similarly to XRAY’s over the last 12 months.

STAA's Price Growth Rating (62) in the Medical Specialties industry is in the same range as XRAY (62). This means that STAA’s stock grew similarly to XRAY’s over the last 12 months.

XRAY's P/E Growth Rating (87) in the Medical Specialties industry is in the same range as STAA (89). This means that XRAY’s stock grew similarly to STAA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
STAAXRAY
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
53%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
57%
Advances
ODDS (%)
Bullish Trend 11 days ago
72%
Bullish Trend 7 days ago
55%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
47%
View a ticker or compare two or three
Interact to see
Advertisement
STAA
Daily Signal:
Gain/Loss:
XRAY
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NDVSX17.300.12
+0.70%
MFS New Discovery Value R2
DFSTX55.400.25
+0.45%
DFA US Small Cap I
POVDX33.290.12
+0.36%
Putnam International Equity R5
APDLX14.740.02
+0.14%
Artisan Value Advisor
RMOMX25.32-0.09
-0.35%
Victory RS Mid Cap Growth Member

STAA and

Correlation & Price change

A.I.dvisor indicates that over the last year, STAA has been loosely correlated with XRAY. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if STAA jumps, then XRAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STAA
1D Price
Change %
STAA100%
+3.27%
XRAY - STAA
53%
Loosely correlated
+1.81%
WST - STAA
44%
Loosely correlated
+1.16%
OFIX - STAA
38%
Loosely correlated
-3.31%
CSTL - STAA
38%
Loosely correlated
+2.85%
IQV - STAA
37%
Loosely correlated
-0.09%
More

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been closely correlated with NVST. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if XRAY jumps, then NVST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
+1.81%
NVST - XRAY
69%
Closely correlated
+4.18%
AZTA - XRAY
56%
Loosely correlated
+2.60%
TFX - XRAY
56%
Loosely correlated
-0.82%
ALGN - XRAY
53%
Loosely correlated
-0.57%
SOLV - XRAY
52%
Loosely correlated
+0.02%
More